Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course and Prognosis

Summary

Study aim is comparison of heart failire with preserved ejection fraction (HFpEF) detection rate in patients with Сhronic Obstructive Pulmonary Disease (COPD) and the clinical course and prognosis in patients with COPD depending on HFpEF presence.

Conditions

• COPD (Chronic Obstructive Pulmonary Disease)
• Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)

Interventions

DIAGNOSTIC_TEST

Echocardiography

Transthoracic echocardiography at rest: with determination of epicardial fat tissue thickness, epicardial adipose tissue thickness (EAT), E/e', interventricular septum thickness, left ventricular posterior wall thickness, and end-diastolic dimension

DIAGNOSTIC_TEST

Spirometry

Spirometry is the most common of the pulmonary function tests, which measures the lung capacity and airway patency (volume and speed of air) during quiet and forced breathing.

DIAGNOSTIC_TEST

Body plethysmography

Body plethysmography is a non-invasive lung function test performed in a sealed booth (body box) that measures total lung volume, functional residual capacity, and airway resistance by using Boyle's Law to track pressure and volume changes as a patient breathes, providing crucial data for diagnosing conditions like COPD and asthma, and differentiating them from other lung disorders

DIAGNOSTIC_TEST

6-Minute Walk Test (6MWT)

The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity

DIAGNOSTIC_TEST

laboratory biomarker analysis

Routine and special laboratory tests

Sponsors & Collaborators

• Kazan State Medical University

  collaborator OTHER

• National Medical Research Center for Therapy and Preventive Medicine

  lead OTHER_GOV

Principal Investigators

• Olga D Dzhioeva, MD, associate professor · National Medical Research Center for Therapy and Preventive Medicine

• Diana I Abdulganieva, MD, professor · Kazan State Medical University

Eligibility

Min Age

50 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-01-01

Primary Completion

2026-12-31

Completion

2026-12-31

Countries

• Russia

Study Locations